Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 3, 2001, Pages 1222-1228

  Laursen, Torben ^a   Gravholt, Claus Højbjerg ^b   Heickendorff, Lene ^b   Drustrup, Jørn ^c   Kappelgaard, Anne Marie ^c   Jørgensen, Jens O L ^b   Christiansen, Jens S ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GROWTH HORMONE; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BONE METABOLISM; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GROWTH HORMONE DEFICIENCY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; STEADY STATE;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BONE AND BONES; CARRIER PROTEINS; FATTY ACIDS, NONESTERIFIED; FEMALE; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; LIPOLYSIS; LIPOPROTEINS; MALE; MIDDLE AGED; PERIODICITY; SOMATOMEDINS;

EID: 0035048752     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.3.1222     Document Type: Article

References (47)

1. Effect of frequency of growth hormone (GH) administration on longitudinal bone growth and body weight in hvpophysectomized rats
2. Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats
3. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion
4. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: Effects on circulating insulin-like growth factor-I and metabolic indices
5. Metabolic response to growth hormone (GH) administered in a pulsatile, continuous or combined pattern
6. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults
7. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients
8. Two weeks of dally injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. I. Effects on insulin-like growth factor-I (IGF-1), GH and IGF binding proteins, and glucose homeostasis
9. Acute down-regulation of the somatogenic receptors in rat liver by a single injection of growth hormone
10. Differential regulation by growth hormone (GH) of insulin-like growth factor I and GH receptor/binding protein gene expression in rat liver
11. The effect of small but sustained elevations in circulating growth hormone on fuel metabolism in growth hormone deficiency
12. Growth hormone and lipids
13. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults
14. Premature mortality due to cardiovascular disease in hypopituitarism
15. Differential effects of continuous versus intermittent administration of growth hormone to hypophysectomized female rats on serum lipoproteins and their apoproteins
16. Growth hormone regulation of serum lipoproteins in the rat: Different growth hormone regulatory principles for apolipoprotein (apo) B and the sexually dimorphic apo E concentrations
17. Evidence for the role of the secretory pattern of growth hormone in the regulation of serum concentrations of cholesterol and apolipoprotein E in rats
18. Continuous but not intermittent administration of growth hormone to hypophysectomized rats increases apolipoprotein-E secretion from cultured hepatocytes
19. MINIMOD: A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test
20. Quantitative estimation of insulin sensitivity
21. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum
22. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II
23. Wick Chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone
24. Blood glucose, lactate, pyruvate, glycerol, 3-hydroxybutyrate and aceto acetate measurements in man using a centrifugal analyser with a fluorimetric attachment
25. Differences in apolipoprotein (a) polymorphism in west Greenland Eskimos and Caucasian Danes
26. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
27. The effect of rate and dose of glucose infusion on the acute insulin response in man
28. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose
29. Toward physiological understanding of glucose tolerance. Minimal-model approach
30. Electrical impedance in assessing human body composition: The BIA-method
31. Different modes of growth hormone (GH) administration do not change GH binding protein activity in man
32. Serum concentrations of growth hormone (GH) binding protein in GH-deficient patients: Impact of mode of GH administration
33. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children
34. Roles of pulsatility and continuity of growth hormone (GH) administration in the regulation of hepatic GH-receptors, and circulating GH-binding protein and insulin-like growth factor-I
35. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action
36. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: A report of one-year clinical experience
37. No seasonal variation of insulin sensitivity and glucose effectiveness in men
38. Lipoprotein(a): Structure, properties and possible involvement in thrombogenesis and atherogenesis
39. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity
40. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients
41. Changes in bone mineral density after discontinuation and early reinstitution of growth hormone (GH) in patients with childhood-onset GH deficiency
42. Markers of bone turnover in the evaluation of the response to growth hormone (GH) treatment in GH-deficient children
43. Three years of growth hormone treatment in growth hormone-deficient adults: Near normalization of body composition and physical performance
44. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
45. Effects of free fatty acids on blood amino acid levels in humans
46. Peak and trough growth hormone concentrations have different associations with the insulin-like growth factor axis, body composition, and metabolic parameters
47. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans